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Anti-TLR2 antibody triggers oxidative
phosphorylation in microglia and increases
phagocytosis of β-amyloid
Ana Rubio-Araiz1* , Orla M. Finucane1, Samuel Keogh1,2 and Marina A. Lynch1
Abstract
Background: Microglia are multifunctional cells that are primarily neuroprotective and a deficit in their functional
integrity is likely to be a contributory factor in the deteriorating neuronal function that occurs with age and
neurodegeneration. One aspect of microglial dysfunction is reduced phagocytosis, and this is believed to contribute to
the accumulation of amyloid-β (Aβ) in Alzheimer’s disease (AD). Therefore, improving phagocytosis should be beneficial
in limiting the amyloidosis that characterises AD.
Methods: Here, we investigated whether an antibody that targets toll-like receptor (TLR)2 might attenuate the
inflammatory and metabolic changes induced by lipopolysaccharide (LPS) and amyloid-β. The impact on phagocytosis
was assessed by immunohistochemistry. We evaluated the metabolic changes with the SeaHorse Extracellular Flux
Analyser and studied the expression of key enzymes driving glycolysis by western blotting. For all experiments,
statistical significance was determined by unpaired Student’s t test and two-way analysis of variance (ANOVA).
Results: We have reported that, when exposed to an inflammatory stimulus, microglia switch their metabolism
towards the metabolically- inefficient glycolysis; this potentially impacts on metabolically demanding functions
like phagocytosis. Anti-TLR2 antibody increased phagocytosis of Aβ in LPS + Aβ-stimulated microglia and this was
linked with the ability of the antibody to attenuate the LPS + Aβ-triggered inflammasome activation. LPS + Aβ
increased glycolysis in microglia and increased the expression of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase
(PFKFB)3, an enzyme that plays a key role in driving glycolysis; these effects were inhibited when cells were incubated
with the anti-TLR2 antibody. The data also show that antibody treatment increased oxidative metabolism.
Conclusions: Thus, microglia with an inflammatory phenotype, specifically cells in which the inflammasome is
activated, are glycolytic; this may compromise the metabolic efficiency of microglia and thereby provide an
explanation for the reduced phagocytic function of the cells. We propose that, by restoring oxidative metabolism
and reducing inflammasome activation in microglia, phagocytic function is also restored.
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Background
The concept that microglia conform to a binary activation
pattern, resting or activated, has been roundly dismissed,
as has the idea that the cells adopt one of two primary ac-
tivation states. Instead, microglia respond to many differ-
ent stimuli in a rather specific manner with the possibility
of adopting multiple different function phenotypes.
In macrophages, it has been shown that inflammatory
stimuli trigger macrophages not only to adopt an inflam-
matory phenotype, but also to switch their metabolism to-
wards glycolysis, thereby rapidly producing the ATP
required to carry out their immune function [1–4]. In-
deed, glycolysis plays a significant role in sustaining the
proinflammatory roles of macrophages because certain
glycolytic enzymes, including pyruvate kinase M2 (PKM2)
and glyceraldehyde 3-phosphate dehydrogenase, modulate
inflammatory cytokine production [5]. In addition, hexoki-
nase 1, which catalyses the first step in glycolysis, and
PKM2, can both lead to activation of the inflammasome
and interleukin (IL)-1β production [6, 7].
Recent evidence from this laboratory has revealed that
microglia, like macrophages, also adopt a glycolytic
phenotype when challenged with an inflammatory stimu-
lus. Specifically, interferon-γ (IFNγ) triggered activation of
primary cultured microglia, increased production of in-
flammatory cytokines and shifted the cells towards
glycolysis [8]. It has also been shown in BV2 cells that
stimulation with lipopolysaccharide (LPS) + IFNγ in-
creased glucose consumption, hexokinase activity and lac-
tate production which are indicative of glycolysis [9],
while LPS alone increased glycolysis and decreased mito-
chondrial metabolism also in BV2 cells [10]. Importantly,
we have demonstrated that microglia prepared from trans-
genic mice that overexpress human amyloid precursor
protein (APP) and presenilin 1 (PS1; APP/PS1 mice) had
both an inflammatory and glycolytic phenotype [8] while
amyloid-β (Aβ) stimulates inflammatory cytokine produc-
tion in LPS-primed microglia [11].
Aβ interacts with several proteins on glia and neurons
including various integrins, immunoglobulin and scaven-
ger receptors, the neurotransmitter receptors, N-methyl-
D-aspartate receptor and α7-nicotinic acetylcholine recep-
tor and the receptor for advanced glycation end products
(RAGE) [12]. However, it has been known for some time
that it also interacts with Toll-like receptor (TLR)2, TLR4
and CD14 on microglia [13–15] triggering signalling
events, including activation of nuclear factor (NF)κβ that
stimulates the production of reactive oxygen species
(ROS) and inflammatory cytokines. TLR2/3 deficiency at-
tenuated the Aβ-induced changes in microglia. Consist-
ently, our data have indicated that Aβ-induced increase in
production of inflammatory cytokines was inhibited by
pre-treating microglia with an anti-TLR2 antibody [16]
and, interestingly, anti-TLR2 antibody prevented the
Aβ-induced decrease in long-term potentiation (LTP),
correlating with the evidence that the interaction of Aβ
with TLR2 is associated with impaired cognition [14]. The
evidence also indicates that administration of anti-TLR2
antibody to APP/PS1 mice improves cognitive function
and this is associated with a decrease in microglial activa-
tion and with a decrease in Aβ accumulation, suggesting
that it may affect phagocytosis [17].
The inflammasome requires two signals to ensure its
activation; the first, for example, a TLR4 agonist, is
responsible for upregulating mRNA expression of IL-1β
and other components of the inflammasome, and the sec-
ond triggers assembly of the inflammasome [18]. It has
been shown that Aβ can act as signal 2 triggering assem-
bly of the inflammasome [19]. Without the two signals,
activation will not occur and therefore inhibiting one of
the signals should prevent inflammasome activation. Since
Aβ interacts to induce at least some of its actions by en-
gaging TLR2, as confirmed by the finding that anti-TLR2
antibody inhibits Aβ-induced changes [16, 17], we argued
that anti-TLR2 antibody would therefore inhibit the
inflammasome and downstream changes.
We aimed to determine whether anti-TLR2 antibody
impacts on the LPS + Aβ-induced activation of the inflam-
masome and therefore on the metabolic and functional
phenotype in microglia. The data indicate that LPS +
Aβ-induced inflammasome activation was indeed inhib-
ited by anti-TLR2 antibody. Aβ phagocytosis by microglia
was increased in LPS-treated microglia that were incu-
bated with anti-TLR2 antibody treated and the phagocytic
cells were lysosomal-associated membrane protein 1
(LAMP1)+ and arginase 1 (Arg1)+. The evidence suggests
that the phagocytic capability of the cells was enhanced
because the metabolic shift to glycolysis induced by LPS +
Aβ was reversed by anti-TLR2 antibody, which also
boosted oxidative metabolism in the cells.
Methods
Cell culture
Microglia were prepared as previously described [16].
Briefly, isolated mixed glia from cortical tissue of neonatal
mice were cultured in T25 cm2 flasks in Dulbecco’s modi-
fied Eagle’s medium (cDMEM) containing foetal bovine
serum (FBS), penicillin and streptomycin (100 U/ml)
supplemented with macrophage colony stimulating factor
(M-CSF; 100 ng/ml; R&D Systems, UK) and granulocyte
macrophage colony stimulating factor (GM-CSF; 100 ng/mL;
R&D Systems, UK) for 10–12 days, after which time
non-adherent microglia were seeded in 24-well plates
(1 × 105cells/well) and cultured for a further 2 days.
Medium was replaced with fresh cDMEM ± LPS
(100 ng/ml; Enzo Life Sciences, UK). After 4 h,
anti-TLR2 antibody (T2.5; OPN-301; a kind gift from
Opsona Therapeutics; 100 nM) was added followed by
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the addition of Aβ (10 μM; Invitrogen, UK) 30 min
later and incubation continued for 24 h; this concentra-
tion was chosen following preliminary data indicat-
ing that this concentration inhibited the LPS +
Aβ-induced increase in IL-1β but did not affect IL-6
and TNFα, or cytokine mRNA expression. The incuba-
tion conditions were chosen because our preliminary
and published evidence showed that the maximum ef-
fect of LPS on release of IL-1β, IL-6 and TNFα was
after a 24 h incubation period and that, although some ef-
fects of Aβ were observed after 6 h incubation [16], other
changes, including an increase in IL-1β mRNA, were not
evident until after 24 h [20]. With respect to the period to
which cells were exposed to anti-TLR2 antibody, we found
that, in our experiments designed to assess the impact of
anti-TLR2 antibody on Aβ-induced changes in long-term
potentiation, a short pre-incubation with the antibody was
optimal [16].
To prepare Aβ, lyophilized Aβ1–40 and Aβ1–42 peptides
were dissolved in HPLC grade water to provide a 6 mg/ml
stock solution, diluted to 1 mg/ml using sterile
phosphate-buffered saline (PBS) and allowed to aggregate
(24 h, 220 rpm, 37 °C). This preparation contains oligo-
mers as evidenced by enhanced Thioflavin T binding (data
not shown). Incubation continued for a further 24 h after
which time cells were harvested for analysis of mRNA,
immunocytochemistry, western immunoblotting or for
analysis of metabolism using Seahorse technology. In
some experiments, the effect of inhibiting oxidative me-
tabolism was assessed by including rotenone in the incu-
bation medium (0.05 μM) for 2 h prior addition of
anti-TLR2 antibody.
Analysis of cytokines by ELISA and RT-PCR
Cytokine concentrations were assessed in supernatant
samples from cultured microglia [21]. Briefly, 96-well
plates (Nunc-Immuno plate with Maxisorp surface,
Denmark) were coated with capture antibody (rat
anti-mouse IL-1β or TNFα antibody (R&D Systems,
USA) and incubated (overnight, room temperature). Du-
plicate samples or standards (50 μl/well) were added and
plates were incubated (24 h, 4 °C) and washed before
addition of detection antibody (biotinylated goat
anti-mouse; 1 h, room temperature). Plates were washed,
incubated with streptavidin-horseradish peroxidase con-
jugate (20 min, room temperature) and washed before
addition of substrate solution (50 μl; 1:1 hydrogen per-
oxide (H2O2): tetramethylbenzidine; R&D Systems,
USA). After colour development, the reaction was
stopped by adding 1 M sulphuric acid (H2SO4; 25 μl)
and plates were read at 450 nm (Labsystem Multiskan
RC, UK). Cytokine mRNA expression was assessed in
harvested microglia by RT-PCR as previously described
[22].
Western immunoblotting
Microglia were prepared for western immunoblotting as
described [11]. Briefly, cells were incubated in lysis buf-
fer (composition in millimolar: Tris-HCl 10, NaCl 50,
Na4P2O7.H2O 10, NaF 50, containing 1% each of Igepal,
phosphatase inhibitor cocktail I and II, and protease in-
hibitor; Sigma, UK), equalised for protein, added to 4×
SDS sample buffer (composition: Tris-HCl 100 mM,
pH 6.8, 4% SDS, 2% bromophenol blue, 20% glycerol;
Sigma, UK), boiled (100 °C, 5 min) and applied to 10%
SDS gels. Proteins were transferred to nitrocellulose
membrane, non-specific binding was blocked and mem-
branes were incubated overnight at 4 °C with the anti-
bodies raised against PFKFB1 or PFKFB3 (both IgG,
raised in rabbit, 1:1000 in 5% non-fat dried milk/TBS-T;
Abcam, USA). Membranes were washed and incubated
(room temperature, 2 h) with a secondary HRP-linked
anti-rabbit antibody (1:5000 in 5% milk in TBS-T).
Immunoreactive bands were detected using Wester-
nBright ECL chemiluminescent substrate (Advansta,
USA). Images were captured using the Fujifilm
LAS-4000 imager, and densitometric analysis was carried
out using ImageJ (http://rsb.info.nih.gov/).
Metabolic analysis
The SeaHorse Extracellular Flux (XF24) Analyser (Sea-
Horse Bioscience, USA) was used to carry out bioener-
getic analysis of cells. Microglia (1 × 105cells/well) were
seeded (100 μl/well) on SeaHorse cell culture microplates
and incubated in cDMEM±LPS (100 ng/ml; Enzo Life
Sciences, UK). After 4 h, anti-TLR2 antibody (100 nM)
was added followed by the addition of Aβ (10 μM; Invitro-
gen, UK) 30 min later. The sensor cartridge was hydrated
by adding SeaHorse XF Calibrant solution (1 ml; SeaHorse
BioScience, USA) to each well of the utility plate and left
overnight in a CO2-free incubator at 37 °C. Following in-
cubation, cells were washed twice with the assay medium
for the mitochondrial stress test or the glycolytic flux test
(1 ml) according to the manufacturer’s instructions, spe-
cific assay media was added to give a final volume of
475 μl/well and the plate was incubated in a CO2-free
incubator (37 °C, 1 h). For the mitochondrial stress test,
oligomycin (20 μM; Abcam, UK), carbonyl cyanide-4-(tri-
fluoromethoxy)phenylhydrazone (20 μM; FCCP; Sigma-
Aldrich, UK) and antimycin A (40 μM; Sigma-Aldrich,
UK) were loaded into the appropriate ports for sequential
delivery. For the glycolytic flux test, glucose (10 mM),
oligomycin (20 μM) and 2-deoxy-D-glucose (2-DG;
500 mM; all Sigma-Aldrich, UK) were prepared in glyco-
lytic flux assay media and similarly loaded into the appro-
priate ports. Following calibration, oxygen consumption
rate (OCR) and extracellular acidification rate (ECAR)
were measured every 8 min for 96 min and the appropri-
ate compounds were injected sequentially at 24 min
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intervals. ECAR and OCR were automatically calculated
using the SeaHorse XF24 software and 4–6 replicates were
assessed for each separate sample.
Confocal image analysis
Microglial cells, plated onto poly-D-lysine-coated cover
slips, were fixed with paraformaldehyde (PFA) (4%;
30 min), washed and blocked by incubation with 10%
NHS and 0.1% Triton X-100 for 1 h and incubated at 4 °C
with the primary antibodies anti-Iba1 (Wako, Japan
1:1000), anti-Aβ 6E10 (Biolegend, USA, 1:500),
anti-LAMP1 (Abcam, UK, 1:250) and anti-Arginase
(Arg)1 (Santa Cruz, USA, 1:500) followed by the second-
ary antibodies Alexa Fluor® 594 donkey anti-rabbit IgG
(1:1000), Alexa Fluor® 488 donkey anti-mouse IgG
(1:1000) and Alexa Fluor® 633 donkey anti-goat IgG
(1:1000) and mounted in ProLong®Gold with the nuclear
marker 4′,6-Diamidine-2′-phenylindole dihydrochloride
(DAPI; Thermo Scientific, USA). Images (10 fields per
experiment, triplicate analysis; × 40 magnification) were
acquired with a Zeiss AX10 Imager A1 microscope. Ana-
lysis of images was undertaken with ImageJ software; the
number of Aβ+ microglia was assessed. Control experi-
ments with each secondary antibody, alone or in combin-
ation, were included and images were acquired
sequentially on a Leica SP8 scanning confocal microscope
for each fluorophore to eliminate cross-signal contamin-
ation. Analysis revealed that anti-TLR2 antibody staining
of Iba1+ cells was confined to the membrane (see
Additional file 1: Figure S2).
Analysis of Aβ engulfment by microglia
For analysis of the effect of LPS on phagocytosis,
microglia (1 × 105cells/well were plated onto coverslips
coated with poly-D-lysine (5 μg/ml; Merck Millipore
Ltd., UK). After 48 h, cells were preincubated with
LPS (100 ng/ml; Ezo Life Sciences, UK) for 4 h then
stimulated for 24 h with Aβ1–40 and Aβ1–42 peptides
(5 μM; Invitrogen, UK), and pulse-centrifuged for
15 s in a benchtop microcentrifuge. This procedure
removed large aggregates and microscopic analysis in-
dicated that that the preparation comprised mainly
oligomers. The ratio of Iba+ cells that engulfed Aβ
was calculated by enumerating the total number of
Iba+ cells and the number of Iba+ Aβ+ cells in 3D
projection images generated from Z stacks using a
Leica SP8 scanning confocal microscope and proc-
essed using LAS AF Lite software. A total of 10 fields
per experiment in triplicate were analysed.
Caspase 1 activity assay
To analyse the activity of caspase 1 in microglia, we used
a commercially available Caspase-1/ICE Colorimetric
Assay (R&D Systems) and we assessed activity in
cultured microglia, which were collected by centrifuga-
tion (250×g, 10 min) in a conical tube. The supernatant
was gently removed and discarded while the cell pellet
was lysed by the addition of cold lysis buffer (25 μl/1 ×
106 cells). The cell lysate was incubated (4 °C, 10 min)
and centrifuged (10,000×g, 1 min). The enzymatic reac-
tion for caspase activity was carried out in a 96-well
flat-bottomed microplate with cell lysate (50 μl), 2X Re-
action Buffer+ 1% DTT (50 μl) and caspase-1 colorimet-
ric substrate (5 μl, YVAD-pNA). The plate was
incubated at 37 °C for 2 h and read on a microplate
reader at a wavelength of 405 nm. The results are
expressed as fold increase in caspase 1 activity in treated
cells relative to control cells.
Statistical analysis
Data are reported as the mean ± SEM and the number
of experiments is indicated in each case. Statistical ana-
lysis was carried out using a one-way analysis of variance
(ANOVA), with Newman-Keuls multiple comparison test.
When comparisons were being made between two con-
ditions, an unpaired Student’s t test was performed. The
significance level was set at p < 0.05.
Results
We assessed phagocytosis of Aβ in microglia treated with
LPS in the presence/absence of anti-TLR2 antibody and
show that cells incubated with LPS + Aβ and anti-TLR2
antibody exhibited an increase in Aβ engulfment
compared with cells incubated with LPS +Aβ (**p < 0.01;
Student’s t test for independent means; Fig. 1a, b).
The lysosomal protein LAMP1 was increased in cells
incubated with LPS + Aβ+anti-TLR2 antibody compared
with those incubated with LPS + Aβ (*p < 0.05; Fig. 2b).
A similar marked increase in Arg1 was observed in cells
incubated with LPS + Aβ+anti-TLR2 antibody compared
with cells incubated with LPS + Aβ (*p < 0.05; Fig. 2c). It
can be inferred from the co-localization of Arg1 and
LAMP1 (Fig. 2a) that Arg1+ cells are effective phago-
cytes. The increased expression of LAMP1 and Arg1 on
cells was associated with a decrease in expression of the
microglial marker Iba1 which is upregulated in inflam-
matory microglia. The data show specifically that Iba1
fluorescence was significantly decreased in cells that
were incubated with LPS + Aβ+anti-TLR2 antibody com-
pared with those incubated with LPS + Aβ (*p < 0.05;
Fig. 2d). The cells incubated with LPS + Aβ+anti-TLR2
antibody also reflects a morphological change that is
consistent with an increase in their phagocytic capacity;
they are larger and more amoeboid.
Anti-TLR2 antibody significantly attenuated the LPS +
Aβ-induced increase in IL-1β (**p < 0.001; ANOVA; LPS
+ Aβ vs control; +p < 0.05; LPS + Aβ vs LPS + Aβ+an-
ti-TLR2 antibody; Fig. 3a). In contrast, while LPS + Aβ
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increased IL-1β mRNA, TNFα mRNA and TNFα secre-
tion (**p < 0.01; ***p < 0.001; ANOVA; Fig. 3b–d),
anti-TLR2 antibody exerted no modulatory effect and
therefore there was a significant difference between the
samples obtained from cells that were incubated with
anti-TLR2 antibody alone compared with the LPS +
Aβ-treated cells that were incubated with anti-TLR2
antibody (p < 0.01; ANOVA; anti-TLR2 antibody vs LPS
+ Aβ+anti-TLR2; Fig. 3b–d). The specific action of
anti-TLR2 antibody on IL-1β secretion suggests that it
may inhibit assembly of the inflammasome and to ex-
plore this further we assessed caspase 1 activity. LPS +
Aβ significantly increased caspase 1 immunoreactivity
(***p < 0.001; ANOVA; Fig. 3e), but this was not modu-
lated when cells were incubated in the presence of
anti-TLR2 antibody. However, caspase 1 activity,
assessed using a fluorometric assay, was increased by
LPS + Aβ (*p < 0.05) and anti-TLR2 antibody attenuated
this LPS + Aβ-induced effect (+p < 0.05; LPS + Aβ vs LPS
+ Aβ+anti-TLR2 antibody; Fig. 3f ). These data suggest
that the phagocytic potential of microglia is diminished
when the inflammasome is activated.
Recent data from this laboratory has indicated that in-
flammatory microglia switch their metabolism to gly-
colysis, and we considered that such a switch, which
effectively reduces ATP production, might negatively im-
pact on phagocytic function. The data indicate that LPS
+ Aβ increased glycolytic capacity (*p < 0.05; ANOVA;
Fig. 4b), and this increase was attenuated by anti-TLR2
antibody (+p < 0.05; LPS + Aβ vs LPS + Aβ+anti-TLR2
antibody). In parallel with the increase in glycolytic cap-
acity, LPS + Aβ significantly increased the inducible, but
not the constitutive, form of PFKFB3 (*p < 0.05;
ANOVA; Fig. 4c, d) and this was also attenuated by
anti-TLR2 antibody (+p < 0.05; LPS + Aβ vs LPS +
Aβ+anti-TLR2 antibody). We investigated the effect of
Aβ and LPS alone on metabolism in microglia. Both
slightly increased glycolysis and glycolytic capacity (see
Additional file 2: Figure S1) but neither alone triggered a
significant change, while the combination of LPS + Aβ
significantly increased glycolysis and glycolytic capacity.
Anti-TLR2 antibody also increased PFKFB1 (+p < 0.05;
LPS + Aβ vs LPS + Aβ+anti-TLR2 antibody; Fig. 4e) and
caused a shift in molecular weight. This might reflect
phosphorylation on Ser32, which has been shown to
modulate its activity resulting in a decrease in glycolytic
flux [23]. Significantly, analysis of OCR indicated that
anti-TLR2 antibody also increased basal respiration and
ATP production (***p < 0.001, *p < 0.05; LPS + Aβ vs LPS
+ Aβ+anti-TLR2 antibody; ANOVA; Fig. 5) although nei-
ther the antibody alone nor LPS + Aβ in the absence of
the antibody exerted an effect on these measures.
To assess whether the metabolic switch caused by
anti-TLR2 antibody is involved in the augmentation of
phagocytic capacity of microglia, cells stimulated with
LPS + Aβ ± anti-TLR2 antibody were treated with rote-
none, which inhibits complex I in the electron transport
chain. We evaluated phagocytosis of Aβ in microglia in
the presence/absence of rotenone and show that cells in-
cubated with LPS + Aβ+ anti-TLR2 antibody and rote-
none exhibited a decrease in Aβ engulfment compared
with cells incubated with LPS + Aβ+α-TLR2 antibody
(***p < 0.001, ++p < 0.01; ANOVA; Fig. 6a, b).
Discussion
The significant finding from these experiments is that
phagocytosis of Aβ is compromised in glycolytic micro-
glia in which the inflammasome is activated by LPS + Aβ
A                 B
Fig. 1 Anti-TLR2 antibody increases phagocytosis of Aβ. Microglia from neonatal mice were plated on poly-D-lysine-coated coverslips, incubated
with LPS (100 ng/ml) for 4 h after which time anti-TLR2 antibody (2.5 mM/ml) was added. Aβ (10 μM) was added 4.5 h later and incubation continued
for 24 h. Cells were harvested, fixed in 4% PFA and stained for Iba1 and Aβ as described in the “Methods” section. a Mean data revealed that
incubation of LPS + Aβ-stimulated cells with anti-TLR2 antibody significantly increased phagocytosis of Aβ (**p < 0.01 LPS + Aβ+anti-TLR2 vs LPS + Aβ;
Student’s t test for independent means; n = 3). Aβ uptake is expressed as a ratio between the number of Aβ+ Iba+ cells as a total number of Iba+ cells.
A total of 10 fields per experiment in triplicate were analysed. b The panel shows confocal fluorescence images at × 63 magnification. The presence of
Aβ (green) is evident in Iba1+ (red) cells that were incubated in LPS + Aβ with anti-TLR2 antibody. (Scale bar = 20 μm)
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and that anti-TLR2 antibody increases Aβ phagocytosis,
which we propose is a consequence of its ability to
switch off inflammasome activation and to reprogramme
the cells towards the metabolically more efficient oxida-
tive phosphorylation.
The finding that anti-TLR2 antibody increased LPS +
Aβ-triggered phagocytosis of Aβ by microglia is consist-
ent with our observation that treatment of APP/PS1
mice with the antibody twice monthly for 7 months
from 7 to 14 months of age reduced Aβ accumulation
[17]. It is also broadly in agreement with previous find-
ings that indicated an increase in Aβ phagocytosis by
primary microglia prepared from TLR2-deficient mice
[15]. Anti-TLR2 antibody also attenuated the LPS +
Aβ-induced increase in Iba1, which confirms that it
exerts a modulatory effect on microglial activation.
Treatment of APP/PS1 mice with anti-TLR2 antibody
reduced CD68 immunoreactivity in the hippocampus
providing further evidence of its modulatory effect on
microglial activation [17].
There is strong evidence that Aβ-induced inflamma-
tory changes are mediated by TLR2; indeed, the critical
domain on TLR2 that enables Aβ binding, and signalling
that drives inflammation, has been identified as the
amino acids EKKA (741–744) in the cytoplasm [15].
Whether this domain also controls phagocytosis of Aβ
remains to be explicitly determined. However, it has
been shown that activation of TLR2 induced phagocyt-
osis of Aβ in microglia [24] while TLR2 deletion in APP/
PS1 mice delayed Aβ plaque formation [15, 25]. In
A
B C D
Fig. 2 Anti-TLR2 antibody increases the expression of Arg1 and LAMP1 and decreases Iba1 expression in microglia. Microglia were prepared and
treated as described in the legend for Fig. 1 and stained for LAMP1, Arg1 and Iba1 as described in the “Methods” section. a The panel shows confocal
fluorescence images at × 40 magnification and shows that Iba1 staining was increased in microglia incubated with LPS + Aβ. LAMP1 staining and Arg1
staining were increased in microglia that were incubated in LPS + Aβ+anti-TLR2 antibody. (Scale bar = 50 μm). b–d Analysis of the mean data indicate
that incubation of LPS + Aβ-stimulated cells with anti-TLR2 antibody significantly increased LAMP1 staining (b) and Arg1 staining c, whereas the significant
LPS + Aβ-induced increase in Iba1 (d) was attenuated when cells were also incubated with the antibody ((F3,11) = 4.53; p= 0.033 one-way ANOVA
*p< 0.05; control vs LPS + Aβ; +p< 0.05: Newman-Keuls multiple comparison test; LPS + Aβ vs LPS + Aβ+anti-TLR2 antibody). Data are expressed as the
percentage of LAMP (a), Arg1 (b) or Iba1 (c) staining in each treatment group vs the control. A total of 10 fields per experiment in triplicate were analysed
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addition to TLR2, Aβ binds to other receptors that have
been proposed to impact on phagocytosis. Fibrillar Aβ
binds to a complex that contains CD36, CD47 and
α6β1-integrin, and this binding triggers engulfment of
Aβ in BV2 cells [26], a role for triggering receptor
expressed on myeloid cells 2 (TREM2) in phagocytosis
has also been described [27] and it has been proposed
that Fc receptors [28] and TLR4 [29] are capable of
phagocytosing Aβ deposits. Here, we show that the lyso-
somal membrane protein, LAMP1 is markedly increased
A B 
C D
E F
Fig. 3 Anti-TLR2 antibody decreases IL-1β secretion from microglia. Microglia were prepared as described in the “Methods” section. Cells were
harvested for analysis of IL-1β and TNFα mRNA by RT-PCR, or for staining of caspase 1, and supernatant samples were collected and assessed for
cytokine concentration. Cell lysate was prepared for analysis of caspase 1 activity using a commercially available kit. a–d LPS + Aβ significantly
increased supernatant concentrations of IL-1β (a) and TNFα (c) and also IL-1β mRNA (b) and TNFα mRNA ((a, (F3,14) = 10.87; p = 0.0010; c, (F3,10)
= 3.386; p = 0.0745; b, (F3,16) = 11.98; p = 0.0004; d, (F3,18) = 17.10; p < 0.0001 one-way ANOVA **p < 0.01; ***p < 0.001; Newman-Keuls multiple
comparison test). Anti-TLR2 antibody significantly attenuated the LPS + Aβ-induced increase in IL-1β but did not affect the changes in IL-1β
mRNA, TNFα or TNFα mRNA. e LPS + Aβ significantly increased caspase 1 expression and activity but was not attenuated after anti-TLR2 treatment
((F3,32) = 10.11; p < 0.0001 one-way ANOVA ***p < 0.001). f Caspase 1 activity was increased by LPS + Aβ (*p < 0.05), and anti-TLR2 antibody attenuates
this LPS + Aβ-induced effect (+p < 0.05; LPS + Aβ vs LPS + Aβ+anti-TLR2 antibody; ((F3,10) = 4.874; p = 0.0326 one-way ANOVA; Newman-Keuls multiple
comparison test). For e and f, data are expressed as the percentage of the caspase 1 expression and activity in each treatment group vs the control;
three independent experiments were performed
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in LPS + Aβ-stimulated cells that were incubated with
anti-TLR2 antibody suggesting an effect of the antibody
on lysosomal function. However, we are unaware of any
experimental data that directly link an increase in
LAMP1 expression in microglia with the phagocytic cap-
ability of cells.
LPS and Aβ together provide the two signals required
to activate the inflammasome; LPS triggers signalling
through the TLR4-NFκB pathway to increase mRNA ex-
pression of IL-1β and the other components of the
inflammasome, while Aβ induces assembly of the
inflammasome. Therefore, as predicted, LPS + Aβ in-
creased IL-1β release and caspase 1 activation. Both LPS
+ Aβ-induced changes were attenuated when cells were
incubated in the presence of anti-TLR2 antibody, and it
is suggested that this occurs because the antibody
blocked one of the two signals, Aβ, required to trigger
inflammasome activation. Clearly anti-TLR2 antibody
will not inhibit TLR4 activation by LPS. Whereas LPS +
Aβ also increased IL-1β mRNA, as well as TNFα mRNA
A B 
C D E
Fig. 4 Anti-TLR2 antibody attenuates the LPS + Aβ-induced glycolytic capacity of microglia. Microglia (1 × 105cells/well) were seeded (100 μl/well)
on SeaHorse cell culture microplates and incubated in cDMEM± LPS (100 ng/ml; Enzo Life Sciences, UK). After 4 h, anti-TLR2 antibody (100 nM)
was added followed by the addition of Aβ (10 μM; Invitrogen, UK) 30 min later, as described in detail in the “Methods” section. a. The bioenergetic
profile of microglia consisting of three baseline measures of ECAR followed by sequential measures following exposure to glucose (10 mM), oligomycin
(20 μM) and 2-deoxy-D-glucose (2-DG; 500 mM) is shown. b LPS + Aβ significantly increased mean glycolytic capacity (*p< 0.05), and this was significantly
attenuated when cells were also incubated with anti-TLR2 antibody (+p< 0.05; LPS + Aβ vs LPS + Aβ+anti-TLR2 antibody; (F3,13) = 4.55; p= 0.026; one-way
ANOVA; Newman-Keuls multiple comparison test). c, d. LPS + Aβ significantly increased the inducible (c) but not the constitutive (d) form of PFKFB3
(*p < 0.05), and anti-TLR2 antibody significantly attenuated the LPS + Aβ-induced change (+p < 0.05; LPS + Aβ vs LPS + Aβ+anti-TLR2 antibody;
(F3,18) = 6.067; p = 0.0059 one-way ANOVA, Newman-Keuls multiple comparison test). e LPS + Aβ did not affect PFKFB1 but incubated with
LPS + Aβ+anti-TLR2 antibody significantly increased PFKFB1 (+p < 0.05; LPS + Aβ vs LPS + Aβ+anti-TLR2 antibody; (F3,18) = 4.594; p = 0.0167
one-way ANOVA, Newman-Keuls multiple comparison test). Representative immunoblots are shown. For c–e, data are expressed as the percentage of
the protein expression in each treatment group vs the control; three independent experiments were performed
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and TNFα release, anti-TLR2 antibody did not modulate
these changes. This implies that the antibody specifically
inhibits the inflammasome rather than exerting a general
anti-inflammatory effect. Significantly, we have reported
that inhibiting the inflammasome with the small mol-
ecule inhibitor, MCC950, increased phagocytosis of Aβ
by microglia [11]. A link between phagocytosis and
inflammasome activation has also been described in
macrophages whereby phagocytosed pathogens can trig-
ger activation by microbial proteins or nucleic acids, or
by altering K+ efflux [30]. In microglia, Aβ phagocytosis
triggers inflammasome assembly because of the subse-
quent release of cathepsin B from lysosomes [19]. The
current finding indicating that inhibiting the inflamma-
some with anti-TLR2 antibody is paralleled by increased
phagocytosis of Aβ suggests that inflammatory microglia
are less phagocytic. On the contrary, the microglia that
engulf Aβ are Arg1+, which is generally thought to be an
indicator of an anti-inflammatory phenotype; this is
consistent with previous findings [31]. Increased
A
B C
D E
Fig. 5 Anti-TLR2 treatment triggers oxidative phosphorylation. Primary microglia were prepared for metabolic analysis as described in the legend
to Fig. 4 and in the “Methods” section. a The OCR bioenergetics profile consisting of three baseline measures of OCR followed by sequential measures
following exposure to oligomycin (20 μM), carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone (20 μM; FCCP) and antimycin A (40 μM) is shown.
b–e LPS + Aβ exerted no significant effect on mean basal respiration b, mean maximal respiration (c) or mean ATP production (d) or mean proton
leak (e) but, except for maximal respiration and proton leak, each measure was significantly increased when cells were incubated in LPS + Aβ+anti-
TLR2 antibody (***p < 0.001, *p < 0.05, +p < 0.05; LPS + Aβ vs LPS + Aβ+anti-TLR2 antibody; (F3,16) = 9.666; p = 0.0010; one-way ANOVA, Newman-Keuls
multiple comparison test); three independent experiments were performed
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arginase 1 suggests that ornithine will ultimately be in-
creased and this is interesting because, at least in macro-
phages, increased ornithine, which is a characteristic of
IL-4-treated cells, is associated with increased phago-
cytic activity [32].
There are very few reports in the literature that have
assessed the impact of inflammatory stimuli on micro-
glial phagocytosis of Aβ specifically. Those that exist
present a conflicting narrative. On the one hand, LPS in-
creased uptake of Cy3-Aβ42 in microglia as assessed by
evaluating the mean fluorescence values for
cell-associated Cy3-Aβ42 while the extracellular signal
was decreased [33]. In contrast, LPS and inflammatory
cytokines decreased phagocytosis of microspheres in
BV2 cells and this effect was inhibited by
anti-inflammatory cytokines [34]. Conflicting data have
also been generated from in vivo experiments. A single
intrahippocampal injection of LPS in Tg2576 APP mice
decreased the Aβ burden 3, 7 and 14 days after injection,
but not 28 days after injection [35]. However, an earlier
study indicated that intraventricular infusion of LPS for
2 weeks exacerbated Aβ deposition in transgenic mice
that overexpressed APP and apolipoprotein E [36].
Here we show that LPS + Aβ increased glycolysis in
microglia, consolidating our recent finding in microglia
[8] and other findings in BV2 cells [9, 10], and showing
that inflammatory stimuli exert this action in microglia
as they do in macrophages [1]. A significant finding of
the current study is that anti-TLR2 antibody attenuated
the LPS + Aβ-induced effect on glycolysis and also on
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase
(PFKFB3), a bifunctional enzyme with predominantly
kinase activity that leads to an increase in phosphofructo-
kinase activity and thereby drives glycolysis [37–39]. Inter-
estingly, the impact of the antibody was observed on the
inducible form of the enzyme and not the constitutive
form. The possibility is that this reflects phosphorylation
of PFKFB1. It has been shown that phosphorylation of
PFKFB1 on ser32 modulates its activity, decreasing glyco-
lytic flux [23]. This is consistent with our finding that
anti-TLR2 antibody, which induces the molecular weight
shift in PFKFB1, increases oxidative metabolism.
It has been shown that glycolytic enzymes impact on
the inflammasome in macrophages [40]. Hexokinase 1 in-
teracts with voltage-dependent anion channel (VDAC)1
which activates the inflammasome while PKM2 triggers
inflammasome activation in a HIF-1α-dependent manner
[41] and also activates eukaryotic translation initiation fac-
tor 2A kinase, which directly interacts with inflammasome
components regulating its assembly [42]. Therefore, it is
possible that LPS + Aβ triggers glycolysis and, as a result,
feeds back to activate the inflammasome. However, LPS +
Aβ-induced glycolysis is attenuated in macrophages from
NLRP3−/− mice (Finucane et al. pers. comm), indicating
A
B
Fig. 6 Rotenone, an inhibitor of oxidative metabolism, overcomes the
stimulatory effect of anti-TLR2 antibody on phagocytosis of Aβ. Microglia
were prepared as described in the legend for Fig. 1 and treated with LPS+
Aβ in the presence or absence of anti-TLR2 antibody and the presence or
absence of rotenone (rot). Cells were stained for Aβ and Iba1 as described
in the “Methods” section. a The panel shows confocal fluorescence images
at × 40 magnification. Sample images are presented that reveal the
presence of Aβ (green) in Iba1+ (red) in cells that were incubated in LPS+
Aβ with anti-TLR2 (left hand images) in the presence or absence of
rotenone (rot; right hand images). The inserts highlights Aβ uptake by an
Iba1+ cell. (Scale bar = 50 μm). b Incubation of microglia in the presence of
LPS+Aβ+anti-TLR2 antibody significantly increased phagocytosis of Aβ
((F3,21) = 19.27; p=0.0378 **p<0.01; one-way ANOVA; Newman-Keuls
multiple comparison test), and this effect is significantly attenuated when
rotenone was added to the incubation (++p<0.01; LPS+Aβ+anti-TLR2
antibody vs LPS+Aβ+anti-TLR2 antibody+rotenone. Aβ uptake is expressed
as a ratio between the number of Aβ+ Iba+ cells as a total number of Iba+
cells. A total of 10 fields per experiment in triplicate were analysed
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that activation of the inflammasome drives signals that in-
duce glycolysis, and this is consistent with the observation
that IL-1β also stimulates glycolysis. Similarly, the primary
modulatory effect of anti-TLR2 antibody on LPS + Aβ-in-
duced changes may be on the metabolic profile of the cells
and, in this context, it is interesting that oxidative metab-
olism was increased in LPS + Aβ-treated cells that were
incubated with the antibody.
Glycolysis is metabolically inefficient, producing only
2 molecules of ATP per glucose, compared with oxida-
tive metabolism which yields ~ 30 molecules of ATP.
Therefore, a persistent bias towards glycolysis may have
a detrimental effect on metabolically expensive processes
like phagocytosis. We demonstrate that phagocytosis of
Aβ is enhanced in microglia when oxidative metabolism
is sustained, and when the LPS + Aβ-induced shift to-
wards glycolysis is prevented, by anti-TLR2 antibody.
This finding is consolidated by the observation that rote-
none, which blocks oxidative metabolism, neutralises the
beneficial effect of anti-TLR2 antibody on phagocytosis
in LPS + Aβ-treated microglia.
Disrupted metabolism, including decreased glucose
utilisation and mitochondrial dysfunction, are recognised
features of AD [43]. Since neurons utilise most of the
energy required by the brain [44] studies have tended to
focus on metabolic changes in these cells. However, as
microglia are arguably the primary neuroprotective cell
in the brain, disruption in their metabolic profile is likely
to contribute to disease. A significant finding in this
study is that microglia shift towards a glycolytic pheno-
type in response to an inflammatory stimulus. A persist-
ent reliance on glycolysis in microglia, because it is
metabolically inefficient, will inevitably lead to reduced
function, including phagocytosis, and may ultimately con-
tribute to changes such as amyloid accumulation in AD.
In this context, it is interesting that microglia from APP/
PS1 mice exhibit a glycolytic phenotype [8].
One of the aims of this study was to investigate the
mechanism by which the accumulation of Aβ in APP/PS1
mice was attenuated by anti-TLR2 antibody [17]. The data
presented suggest that the antibody increases Aβ phago-
cytosis by microglia and that this is a consequence of its
action on the metabolic profile of microglia. It is signifi-
cant that the phagocytic microglia are Arg1+ suggesting
that they have an antiinflammatory phenotype, and this is
also suggested by the fact that the antibody-driven in-
crease in phagocytosis is associated with a decrease in
inflammasome activation. We have shown that inhibiting
the inflammasome with MCC950 increased phagocytosis
of Aβ by microglia and decreased Aβ accumulation in
hippocampus of APP/PS1 mice. We propose that the
metabolic signature of microglia impacts on their inflam-
matory status and on their functional integrity, and it re-
mains to be determined whether blocking the actions of
Aβ with anti-TLR2 antibody in APP/PS1 mice will primar-
ily affect the metabolic profile and consequently restore
cell function.
Conclusions
The data demonstrate that targeting TLR2 increases
phagocytosis and lysosomal activity in microglial cell
cultures, and this was accompanied by an inhibition of in-
flammatory changes, and specifically inflammasome
activation, induced by LPS +Aβ. Anti-TLR2 antibody trig-
gers oxidative phosphorylation in microglia and conse-
quently increases phagocytosis of Aβ.
Additional files
Additional file 1: Figure S2. Expression of TLR2 in microglia. Microglia
were prepared and treated as described in the legend for Fig. 1 and stained
for TLR2 incubating with the primary antibody anti-TLR2 (Abcam, UK)
followed by the secondary antibody Alexa Fluor® 488 donkey anti-mouse
IgG (1:1000) and mounted in ProLong®Gold with the nuclear marker DAPI
(Thermo Scientific, USA). The panel shows fluorescence images at × 40
magnification and shows that TLR2 staining is confined to the membrane
of the microglial cells independently of the experimental groups observed.
(Scale bar = 50 μm). (PNG 694 kb)
Additional file 2: Figure S1. Anti-TLR2 antibody attenuates the LPS +
Aβ-induced glycolytic capacity of microglia but has no effect of LPS-
induced or Aβ-induced changes. Microglia were assessed for their meta-
bolic profile using SeaHorse technology following incubation with LPS,
Aβ or both in the presence or absence of anti-TLR2 antibody as de-
scribed in the “Methods” section. LPS + Aβ significantly increased mean
glycolytic capacity and glycolysis (*p < 0.05). The LPS + Aβ-induced effect
on glycolytic capacity was significantly attenuated when cells were also in-
cubated with anti-TLR2 antibody (+p < 0.05; LPS + Aβ vs LPS + Aβ+anti-TLR2
antibody). The modulatory effect of the anti-TLR2 antibody on LPS + Aβ-in-
duced glycolysis did not reach statistical significance. (PNG 67 kb)
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